Announcement time of this financial report: 2023-10-27 19:57:42
Pharmaceutical Easy Buy (stock code: 300937) is an enterprise that plays an important role in the pharmaceutical distribution industry, providing drug sales and distribution services to consumers. As health reform policies deepen and people pay more attention to healthy living, the pharmaceutical distribution market has ushered in new development opportunities. Drug E-Buy plays an important role in this industry, providing drug sales and distribution services to consumers.
In terms of assets and liabilities, E-Pharma's total assets for the third quarter of 2023 were 1,625 billion yuan, up from 1,592 billion yuan at the end of the previous year. Total liabilities were $776 million, a slight increase from $772 million at the end of the previous year. Net assets were $849 million, up from $820 million at the end of the previous year. The balance ratio was 47.74%, down from 48.48% at the end of the previous year.
In terms of profit, E-Pharma's operating revenue for the third quarter of 2023 was 3,212 billion yuan, up from 2,683 billion yuan in the same period last year. Operating profit was 60.452 million yuan, a significant increase from 14.4956 million yuan in the same period last year. Net profit was 49.645,700 yuan, a significant increase from 9.4244 million yuan in the same period last year. This indicates an increase in the company's profitability.
In terms of cash flow, the net cash flow generated by Pharmaceutical Tesco's operating activities in the third quarter of 2023 was -129 million yuan, down from 289.785 million yuan in the same period last year. Cash inflows from operating activities totaled $3,262 billion, up from $2.191 billion in the same period last year. The total cash outflow from operating activities was $3.391 billion, up from $2.162 billion in the same period last year. This shows that the company has had a lot of cash outflow, mainly due to operating cash outflows due to the opening of bank guarantees to freeze funds.
In summary, Yakuto's operating conditions in the third quarter of 2023 were generally good. Profitability increased, but there was a lot of cash outflow. It is expected that the out-of-hospital market will continue to grow in the future, becoming a major growth point in the pharmaceutical distribution market.
For investors, the performance growth and industry prospects of E-Pharmaceutical Co., Ltd. are worth paying attention to. However, at the same time, it is also important to note that the company has a large cash outflow, which may put some pressure on the company's operations. Therefore, investors should comprehensively consider the company's business conditions and industry prospects when making investment decisions.
This article only represents the judgments made by analysts themselves or analysts based on AI analysis. It cannot be used as an investment indicator, nor does it constitute any investment advice. The original purpose of this article was to help investors analyze and judge capital market data in the most intuitive and fastest way and from the most professional perspective.